Monte Rosa Therapeutics, Inc. (NASDAQ: GLUE) is a Healthcare company (Biotechnology) with a market capitalization of $775M. The Maz Rating grades it against the other companies in its sector.
Monte Rosa Therapeutics, Inc.'s current Maz Rating and its five factor grades are for members: log in to see them.
At $9.07, Monte Rosa Therapeutics, Inc. trades at 11.0x sales and 1.9x book value. Over the last twelve months it generated about $71M of revenue and a net loss of $147M. It runs a gross margin of 97.1%, an operating margin of -214.5% and a net margin of -186.2%. It shows return on equity of -30.1%, return on invested capital of -23.6% and a free cash flow yield of -22.5%. On the balance sheet: a debt-to-equity ratio of 0.07 and a current ratio of 10.32. Over the past 52 weeks the share price ranged from $8.83 to $25.77, with a beta of 1.38.
Monte Rosa Therapeutics, Inc. does not currently pay a dividend.
10 Wall Street analyst ratings cover the stock: 8 Buy and 2 Hold, for a Buy consensus. This is the sell side's view, separate from the Maz Rating.
Figures are trailing twelve months unless stated. The Maz Rating and Maz Dividend Score rank a company against its own sector; they are not price targets or recommendations.